Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04315025
Other study ID # CT/RP/02/2018
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 7, 2018
Est. completion date September 20, 2019

Study information

Verified date March 2020
Source PT. Prodia Stem Cell Indonesia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will perform UC-MSCs and CM transplantation. The first group will be injected by UCMSC+NaCl. the 2nd group will be injected by UC-MSC+CM. the 3rd group will be injected by CM. Each group consists of 6 subjects. all groups will be transplanted via peribulbar route. the dosage of UC-MSC is 1 million cells for each subject. All groups will be observed until 6 months.


Description:

The eyes which will give the transplant should be given an aseptic and antiseptic technique to prevent the contamination from the inside and outside. Sterile cover attached to other parts of the face except for the eyes. 1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension (for UC-MSC + NaCl group). Stem cell suspension will be injected by peribulbar and if the injection was done, patients will be given a quinolone antibiotic. On day 1st and day 7th after therapy, patients will be observed the presence of infection, inflammation, and increasing of eye pressure. On day 7th, day 30th, and day 90th after therapy, patients will do a visual field test, visual acuity test, electroretinography, funduscopy, and Optical Coherence Tomography examination. The observation results will be written in the observation table and analyzed by a statistic. After the data was completed, then make a discussion, conclusion, and suggestion of the study.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date September 20, 2019
Est. primary completion date June 20, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Visual field defects at initial examination with Humhprey perimetry are between 25% to 50%

- Willing to sign informed consent as research subjects

- Willing to do peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue

- Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherrent Tomography (OCT) examinations, electroretinogram examinations and fill out a quality of life questionnaire

Exclusion Criteria:

- Pregnant or nursing women

- Positive result of HIV test

- Have a history of eye tumors

- In immunosuppressive treatment or other drugs that can affect the growth of transplanted stem cells

- Have another eye disease such as diabetic retinopathy, uveitis, cataract, and glaucoma

- Do not come to control according to the schedule determined by the researcher (loss to follow up)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
Conditioned Medium (CM)
Conditioned Medium (CM) injected by peribulbar

Locations

Country Name City State
Indonesia Jakarta Eye Center Hospital Jakarta DKI Jakarta
Indonesia Sardjito Hospital Yogyakarta Special Region

Sponsors (1)

Lead Sponsor Collaborator
PT. Prodia Stem Cell Indonesia

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Acuity Test a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6. 1 week after injection
Primary Visual Acuity Test a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6. 1 month after injection
Primary Visual Acuity Test a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6. 3 months after injection
Primary Visual Field Test a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humprey's perimetry. 1 week after injection
Primary Visual Field Test a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humprey's perimetry. 1 month after injection
Primary Visual Field Test a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humprey's perimetry. 3 months after injection
Primary Funduscopy an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist. 1 week after injection
Primary Funduscopy an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist. 1 month after injection
Primary Funduscopy an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist. 3 months after injection
Primary Electrorectinography an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist. 1 week after injection
Primary Electrorectinography an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist. 1 month after injection
Primary Electrorectinography an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist. 3 months after injection
Primary Optical Coherence Tomography (OCT) is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities 1 week after injection
Primary Optical Coherence Tomography (OCT) is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities 1 month after injection
Primary Optical Coherence Tomography (OCT) is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities 3 months after injection
Primary Angiography a process of taking photos of the retina by injecting fluorescent to get a bleeding location on the retina. 1 week after injection
Primary Angiography a process of taking photos of the retina by injecting fluorescent to get a bleeding location on the retina. 1 month after injection
Primary Angiography a process of taking photos of the retina by injecting fluorescent to get a bleeding location on the retina. 3 months after injection
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT01835002 - Transcorneal Electrical Stimulation - Multicenter Safety Study N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2